# Liver Disease Diagnosis and Treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the epidemiology, diagnosis, management, and pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD). It covers topics such as liver fibrosis, insulin resistance, hepatic steatosis, metabolic syndrome, nonalcoholic steatohepatitis (NASH), and non-invasive assessment methods. The papers also discuss the association of NAFLD with hepatocellular carcinoma and its impact on public health. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10351 |
| Works | 1,191 |

## Topic papers all

Showing 15 of 1191.

- [EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection](https://scholariq.org/papers/easl-2017-clinical-practice-guidelines-on-the-management-of-hepatitis-b-virus/)
- [Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention](https://scholariq.org/papers/global-burden-of-nafld-and-nash-trends-predictions-risk-factors-and-prevention/)
- [Use and Abuse of HOMA Modeling](https://scholariq.org/papers/use-and-abuse-of-homa-modeling/)
- [A Model to Predict Survival in Patients With End–Stage Liver Disease](https://scholariq.org/papers/a-model-to-predict-survival-in-patients-with-end-stage-liver-disease-2/)
- [A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement](https://scholariq.org/papers/a-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-an/)
- [AASLD guidelines for the treatment of hepatocellular carcinoma](https://scholariq.org/papers/aasld-guidelines-for-the-treatment-of-hepatocellular-carcinoma/)
- [The Global Epidemic of the Metabolic Syndrome](https://scholariq.org/papers/the-global-epidemic-of-the-metabolic-syndrome/)
- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [NAFLD: A multisystem disease](https://scholariq.org/papers/nafld-a-multisystem-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis](https://scholariq.org/papers/easl-clinical-practice-guidelines-for-the-management-of-patients-with/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [Baveno VII – Renewing consensus in portal hypertension](https://scholariq.org/papers/baveno-vii-renewing-consensus-in-portal-hypertension/)
- [Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome](https://scholariq.org/papers/nonalcoholic-fatty-liver-steatohepatitis-and-the-metabolic-syndrome/)
- [Nonalcoholic Fatty Liver Disease](https://scholariq.org/papers/nonalcoholic-fatty-liver-disease/)

## Topic primary papers

Showing 15 of 493.

- [Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention](https://scholariq.org/papers/global-burden-of-nafld-and-nash-trends-predictions-risk-factors-and-prevention/)
- [Use and Abuse of HOMA Modeling](https://scholariq.org/papers/use-and-abuse-of-homa-modeling/)
- [A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement](https://scholariq.org/papers/a-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-an/)
- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [NAFLD: A multisystem disease](https://scholariq.org/papers/nafld-a-multisystem-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome](https://scholariq.org/papers/nonalcoholic-fatty-liver-steatohepatitis-and-the-metabolic-syndrome/)
- [Nonalcoholic Fatty Liver Disease](https://scholariq.org/papers/nonalcoholic-fatty-liver-disease/)
- [Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease](https://scholariq.org/papers/sampling-variability-of-liver-biopsy-in-nonalcoholic-fatty-liver-disease/)
- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis](https://scholariq.org/papers/a-placebo-controlled-trial-of-subcutaneous-semaglutide-in-nonalcoholic/)
- [Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease](https://scholariq.org/papers/risk-of-cardiovascular-disease-in-patients-with-nonalcoholic-fatty-liver-disease/)
- [Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis](https://scholariq.org/papers/global-perspectives-on-nonalcoholic-fatty-liver-disease-and-nonalcoholic/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.